Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Open Medicine

formerly Central European Journal of Medicine

Editor-in-Chief: Darzynkiewicz, Zbigniew

1 Issue per year


IMPACT FACTOR 2016 (Open Medicine): 0.294
IMPACT FACTOR 2016 (Central European Journal of Medicine): 0.116

CiteScore 2016: 0.28

SCImago Journal Rank (SJR) 2015: 0.140
Source Normalized Impact per Paper (SNIP) 2015: 0.154

Open Access
Online
ISSN
2391-5463
See all formats and pricing
More options …
Volume 6, Issue 5 (Oct 2011)

Issues

Investigating gene expression profile of non-small cell lung cancer

Tõnu Vooder
  • medical faculty, Lung Clinic, Tartu University, 51014, Tartu, Estonia
  • Institute of Molecular and Cell Biology, Department of Biotechnology, Tartu University, 51010, Tartu, Estonia
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Andres Metspalu
  • Institute of Molecular and Cell Biology, Department of Biotechnology, Tartu University, 51010, Tartu, Estonia
  • Estonian Genome Foundation, 51010, Tartu, Estonia
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2011-08-09 | DOI: https://doi.org/10.2478/s11536-011-0063-8

Abstract

Lung cancer is mainly a lifestyle-associated disease with poor prognosis and the lowest five year survival rate of all types of cancer. Lung cancers are divided into two main groups: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Surgical treatment is generally indicated in cases of early stage NSCLC, and those patients treated with radical and aggressive surgery have a somewhat better survival rate. The main problems with lung cancer treatment are due to late diagnosis, rapidly developing drug resistance and side effects of the treatment that are experienced by almost all patients. The next step for distinguishing histologically complicated lung cancers and determining optimal treatment strategies is gene expression analysis. Supported by gene expression data, it is possible to prognosticate the course of the disease.

Keywords: Lung cancer; Non-small cell lung cancer; Gene expression; Microchip; Molecular markers

  • [1] Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009 Jul–Aug;59(4):225–249 http://dx.doi.org/10.3322/caac.20006CrossrefGoogle Scholar

  • [2] Levi F, Lucchini F, Negri E, La Vecchia C. Trends in mortality from major cancers in the European Union, including acceding countries, in 2004. Cancer. 2004 Dec 15;101(12):2843–2850 http://dx.doi.org/10.1002/cncr.20666CrossrefGoogle Scholar

  • [3] Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007 Jan;12(1):20–37 http://dx.doi.org/10.1634/theoncologist.12-1-20CrossrefGoogle Scholar

  • [4] Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer. 1999 Nov 1;86(9):1867–1876 http://dx.doi.org/10.1002/(SICI)1097-0142(19991101)86:9<1867::AID-CNCR31>3.0.CO;2-9CrossrefGoogle Scholar

  • [5] Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: looking to the future. J Clin Oncol. 2005 May 10;23(14):3175–3185 http://dx.doi.org/10.1200/JCO.2005.10.462CrossrefGoogle Scholar

  • [6] Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J. 2001 Dec;18(6):1059–1068 http://dx.doi.org/10.1183/09031936.01.00275301CrossrefGoogle Scholar

  • [7] Anbazhagan R, Tihan T, Bornman DM, Johnston JC, Saltz JH, Weigering A, et al. Classification of small cell lung cancer and pulmonary carcinoid by gene expression profiles. Cancer Res. 1999 Oct 15;59(20):5119–5122 Google Scholar

  • [8] Linnoila RI, Piantadosi S, Ruckdeschel JC. Impact of neuroendocrine differentiation in non-small cell lung cancer. The LCSG experience. Chest. 1994 Dec;106(6 Suppl):367S–371S http://dx.doi.org/10.1378/chest.106.6.367SCrossrefGoogle Scholar

  • [9] Okubo C, Minami Y, Tanaka R, Uchihara T, Anami Y, Furuya S, et al. Analysis of differentially expressed genes in neuroendocrine carcinomas of the lung. J Thorac Oncol. 2006 Oct;1(8):780–786 http://dx.doi.org/10.1097/01243894-200610000-00005CrossrefGoogle Scholar

  • [10] Wistuba, II, Berry J, Behrens C, Maitra A, Shivapurkar N, Milchgrub S, et al. Molecular changes in the bronchial epithelium of patients with small cell lung cancer. Clin Cancer Res. 2000 Jul;6(7):2604–2610 Google Scholar

  • [11] Nevins JR, Potti A. Mining gene expression profiles: expression signatures as cancer phenotypes. Nat Rev Genet. 2007 Aug;8(8):601–609 http://dx.doi.org/10.1038/nrg2137Web of ScienceCrossrefGoogle Scholar

  • [12] Toffalorio F, Giovannetti E, De Pas T, Radice D, Pelosi G, Manzotti M, et al. Expression of gemcitabine- and cisplatin-related genes in nonsmall-cell lung cancer. The pharmacogenomics journal. 2009 Nov 10 Web of ScienceGoogle Scholar

  • [13] Raponi M, Zhang Y, Yu J, Chen G, Lee G, Taylor JM, et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res. 2006 Aug 1;66(15):7466–7472 http://dx.doi.org/10.1158/0008-5472.CAN-06-1191CrossrefGoogle Scholar

  • [14] Gray J, Simon G, Bepler G. Molecular predictors of chemotherapy response in non-small-cell lung cancer. Expert Rev Anticancer Ther. 2007 Apr;7(4):545–549 http://dx.doi.org/10.1586/14737140.7.4.545CrossrefWeb of ScienceGoogle Scholar

  • [15] Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000 Feb 3;403(6769):503–511 http://dx.doi.org/10.1038/35000501CrossrefGoogle Scholar

  • [16] Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790–13795 http://dx.doi.org/10.1073/pnas.191502998CrossrefGoogle Scholar

  • [17] van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002 Dec 19;347(25):1999–2009 http://dx.doi.org/10.1056/NEJMoa021967CrossrefGoogle Scholar

  • [18] Cooper D. The Molecular Genetics of Lung Cancer. Heidelberg: Springer-Verlag 2005 Google Scholar

  • [19] Thomas L, Doyle LA, Edelman MJ. Lung cancer in women: emerging differences in epidemiology, biology, and therapy. Chest. 2005 Jul;128(1):370–381 http://dx.doi.org/10.1378/chest.128.1.370CrossrefGoogle Scholar

  • [20] Dennis JL, Vass JK, Wit EC, Keith WN, Oien KA. Identification from public data of molecular markers of adenocarcinoma characteristic of the site of origin. Cancer Res. 2002 Nov 1;62(21):5999–6005 Google Scholar

  • [21] Giordano TJ, Shedden KA, Schwartz DR, Kuick R, Taylor JM, Lee N, et al. Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. Am J Pathol. 2001 Oct;159(4):1231–1238 http://dx.doi.org/10.1016/S0002-9440(10)62509-6CrossrefGoogle Scholar

  • [22] Vooder T, Valk K, Kolde R, Roosipuu R, Vilo J, Metspalu A. Gene Expression-Based Approaches in Differentiation of Metastases and Second Primary Tumour. Case Rep Oncol.3(2):255–261 Google Scholar

  • [23] Bridgewater J, van Laar R, Floore A, Van TVL. Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary. British journal of cancer. 2008 Apr 22;98(8):1425–1430 http://dx.doi.org/10.1038/sj.bjc.6604315CrossrefGoogle Scholar

  • [24] Wigle DA, Jurisica I, Radulovich N, Pintilie M, Rossant J, Liu N, et al. Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res. 2002 Jun 1;62(11):3005–3008 Google Scholar

  • [25] Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. 2002 Aug; 8(8):816–824 Google Scholar

  • [26] Bianchi F, Nuciforo P, Vecchi M, Bernard L, Tizzoni L, Marchetti A, et al. Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J Clin Invest. 2007 Oct 18 Google Scholar

  • [27] Lu Y, Lemon W, Liu PY, Yi Y, Morrison C, Yang P, et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med. 2006 Dec;3(12):e467 http://dx.doi.org/10.1371/journal.pmed.0030467CrossrefGoogle Scholar

  • [28] Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 2007 Feb 22;356(8):800–808 http://dx.doi.org/10.1056/NEJMoa065411CrossrefGoogle Scholar

  • [29] Tomida S, Koshikawa K, Yatabe Y, Harano T, Ogura N, Mitsudomi T, et al. Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene. 2004 Jul 8;23(31):5360–5370 http://dx.doi.org/10.1038/sj.onc.1207697CrossrefGoogle Scholar

  • [30] Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med. 2007 Jan 4;356(1):11–20 http://dx.doi.org/10.1056/NEJMoa060096CrossrefWeb of ScienceGoogle Scholar

  • [31] Lau SK, Boutros PC, Pintilie M, Blackhall FH, Zhu CQ, Strumpf D, et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol. 2007 Dec 10;25(35):5562–5569 http://dx.doi.org/10.1200/JCO.2007.12.0352CrossrefGoogle Scholar

  • [32] Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer. 2003 Oct;3(10):733–744 http://dx.doi.org/10.1038/nrc1190CrossrefGoogle Scholar

  • [33] Powell CA, Spira A, Derti A, DeLisi C, Liu G, Borczuk A, et al. Gene expression in lung adenocarcinomas of smokers and nonsmokers. Am J Respir Cell Mol Biol. 2003 Aug;29(2):157–162 http://dx.doi.org/10.1165/rcmb.2002-0183RCCrossrefGoogle Scholar

  • [34] Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007 Sep;132(3 Suppl):29S–55S http://dx.doi.org/10.1378/chest.07-1347CrossrefGoogle Scholar

  • [35] Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol. 2006 May 10;24(14):2158–2163 http://dx.doi.org/10.1200/JCO.2006.06.5961CrossrefGoogle Scholar

  • [36] Cerfolio RJ, Bryant AS, Scott E, Sharma M, Robert F, Spencer SA, et al. Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest. 2006 Dec;130(6):1796–1802 http://dx.doi.org/10.1378/chest.130.6.1796CrossrefGoogle Scholar

  • [37] Planchard D, Loriot Y, Goubar A, Commo F, Soria JC. Differential expression of biomarkers in men and women. Seminars in oncology. 2009 Dec;36(6):553–565 http://dx.doi.org/10.1053/j.seminoncol.2009.09.004CrossrefWeb of ScienceGoogle Scholar

  • [38] Wei Q, Cheng L, Amos CI, Wang LE, Guo Z, Hong WK, et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst. 2000 Nov 1;92(21):1764–1772 http://dx.doi.org/10.1093/jnci/92.21.1764CrossrefGoogle Scholar

  • [39] Wei Z, Lifen J, Jiliang H, Jianlin L, Baohong W, Hongping D. Detecting DNA repair capacity of peripheral lymphocytes from cancer patients with UVC challenge test and bleomycin challenge test. Mutagenesis. 2005 Jul;20(4):271–277 http://dx.doi.org/10.1093/mutage/gei037CrossrefGoogle Scholar

  • [40] Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006 Sep 7;355(10):983–991 http://dx.doi.org/10.1056/NEJMoa060570CrossrefGoogle Scholar

  • [41] Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinumbased chemotherapy. Clin Cancer Res. 2004 Aug 1;10(15):4939–4943 http://dx.doi.org/10.1158/1078-0432.CCR-04-0247CrossrefGoogle Scholar

About the article

Published Online: 2011-08-09

Published in Print: 2011-10-01


Citation Information: Open Medicine, ISSN (Online) 2391-5463, DOI: https://doi.org/10.2478/s11536-011-0063-8.

Export Citation

© 2011 Versita Warsaw. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. BY-NC-ND 3.0

Comments (0)

Please log in or register to comment.
Log in